CA3066190A1 - Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis - Google Patents
Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis Download PDFInfo
- Publication number
- CA3066190A1 CA3066190A1 CA3066190A CA3066190A CA3066190A1 CA 3066190 A1 CA3066190 A1 CA 3066190A1 CA 3066190 A CA3066190 A CA 3066190A CA 3066190 A CA3066190 A CA 3066190A CA 3066190 A1 CA3066190 A1 CA 3066190A1
- Authority
- CA
- Canada
- Prior art keywords
- day
- patient
- gnrh antagonist
- administered
- amh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515268P | 2017-06-05 | 2017-06-05 | |
| US62/515,268 | 2017-06-05 | ||
| PCT/EP2018/064768 WO2018224498A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3066190A1 true CA3066190A1 (en) | 2018-12-13 |
Family
ID=62620835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3066190A Pending CA3066190A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11980621B2 (enExample) |
| EP (1) | EP3634418A1 (enExample) |
| JP (2) | JP7348171B2 (enExample) |
| KR (2) | KR102839190B1 (enExample) |
| CN (1) | CN110996956A (enExample) |
| AU (2) | AU2018280742B2 (enExample) |
| CA (1) | CA3066190A1 (enExample) |
| EA (1) | EA201992612A1 (enExample) |
| MA (1) | MA49256A (enExample) |
| MX (1) | MX2019014483A (enExample) |
| SG (1) | SG11201911598WA (enExample) |
| WO (1) | WO2018224498A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| EP3634418A1 (en) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| US11759464B2 (en) | 2017-06-05 | 2023-09-19 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| WO2020089190A2 (en) | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| KR20220061120A (ko) * | 2019-08-08 | 2022-05-12 | 옵스에파 에스에이 | 에스트로겐-의존성 장애 치료용 조성물 및 방법 |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| MX2022015003A (es) | 2020-05-29 | 2023-03-03 | Myovant Sciences Gmbh | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. |
| WO2022101303A1 (en) * | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| WO2022179469A1 (zh) * | 2021-02-23 | 2022-09-01 | 南京明德新药研发有限公司 | 噻吩并嘧啶二酮类化合物及其应用 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342760A (en) | 1992-06-10 | 1994-08-30 | Abbott Laboratories | Determination of estradiol by competitive immunoassay |
| US5663054A (en) | 1995-03-03 | 1997-09-02 | Abbott Laboratories | Determination of steroids by competitive immunoassay |
| US7109171B2 (en) | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| WO2002002533A1 (en) | 2000-07-05 | 2002-01-10 | Yamanouchi Pharmaceutical Co., Ltd. | Propane-1,3-dione derivatives |
| ZA200506611B (en) | 2003-01-29 | 2006-12-27 | Takeda Pharmaceutical | Thienopyrimidine compounds and use thereof |
| WO2005007165A1 (en) | 2003-07-07 | 2005-01-27 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| EP1864976B1 (en) | 2005-03-31 | 2012-10-10 | Astellas Pharma Inc. | Propane-1,3-dion derivative or salt thereof |
| PT1939204E (pt) * | 2005-10-19 | 2013-03-14 | Kissei Pharmaceutical | Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| EP2535342B1 (en) | 2010-02-10 | 2014-08-06 | Kissei Pharmaceutical Co., Ltd. | Salt of fused heterocyclic derivative and crystal thereof |
| CN104169287A (zh) | 2012-01-16 | 2014-11-26 | 拜耳知识产权有限责任公司 | 作为促性腺激素释放激素受体拮抗剂的螺二氢吲哚衍生物 |
| WO2013126517A1 (en) | 2012-02-21 | 2013-08-29 | Northwestern University | Anti-mullerian hormone detection in whole blood |
| KR20150048762A (ko) | 2012-09-07 | 2015-05-07 | 아스텔라스세이야쿠 가부시키가이샤 | 술포닐아미딘 화합물의 제조법 |
| JP6268093B2 (ja) | 2012-09-14 | 2018-01-24 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| SMT202200255T1 (it) | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| AR095785A1 (es) | 2013-04-09 | 2015-11-11 | Bayer Pharma AG | Derivados de espiroindolina y composiciones farmacéutica de los mismos |
| CA3002791A1 (en) | 2015-09-01 | 2017-03-09 | Abbvie Inc. | Methods of administering elagolix |
| AU2017309015B2 (en) | 2016-08-08 | 2022-09-15 | Kissei Pharmaceutical Co., Ltd. | Administration and dosage of therapeutic agent for endometriosis |
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| US11759464B2 (en) | 2017-06-05 | 2023-09-19 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| EP3634418A1 (en) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| KR20210100623A (ko) | 2018-11-07 | 2021-08-17 | 옵스에파 에스에이 | 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법 |
-
2018
- 2018-06-05 EP EP18731378.8A patent/EP3634418A1/en active Pending
- 2018-06-05 US US16/619,776 patent/US11980621B2/en active Active
- 2018-06-05 CA CA3066190A patent/CA3066190A1/en active Pending
- 2018-06-05 AU AU2018280742A patent/AU2018280742B2/en active Active
- 2018-06-05 MX MX2019014483A patent/MX2019014483A/es unknown
- 2018-06-05 KR KR1020197038977A patent/KR102839190B1/ko active Active
- 2018-06-05 CN CN201880050650.3A patent/CN110996956A/zh active Pending
- 2018-06-05 EA EA201992612A patent/EA201992612A1/ru unknown
- 2018-06-05 JP JP2020516959A patent/JP7348171B2/ja active Active
- 2018-06-05 KR KR1020257024754A patent/KR20250117836A/ko active Pending
- 2018-06-05 SG SG11201911598WA patent/SG11201911598WA/en unknown
- 2018-06-05 MA MA049256A patent/MA49256A/fr unknown
- 2018-06-05 WO PCT/EP2018/064768 patent/WO2018224498A1/en not_active Ceased
-
2023
- 2023-05-23 JP JP2023084336A patent/JP7657855B2/ja active Active
-
2024
- 2024-03-14 AU AU2024201701A patent/AU2024201701B2/en active Active
- 2024-04-12 US US18/634,241 patent/US20240293414A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020522571A (ja) | 2020-07-30 |
| WO2018224498A1 (en) | 2018-12-13 |
| AU2024201701A1 (en) | 2024-04-04 |
| KR20250117836A (ko) | 2025-08-05 |
| KR102839190B1 (ko) | 2025-07-28 |
| MA49256A (fr) | 2021-05-26 |
| MX2019014483A (es) | 2020-08-17 |
| US11980621B2 (en) | 2024-05-14 |
| EP3634418A1 (en) | 2020-04-15 |
| AU2018280742A1 (en) | 2020-01-30 |
| CN110996956A (zh) | 2020-04-10 |
| JP7348171B2 (ja) | 2023-09-20 |
| US20200138819A1 (en) | 2020-05-07 |
| KR20200027481A (ko) | 2020-03-12 |
| AU2018280742B2 (en) | 2023-12-21 |
| JP2023113715A (ja) | 2023-08-16 |
| AU2024201701B2 (en) | 2025-04-10 |
| SG11201911598WA (en) | 2020-01-30 |
| US20240293414A1 (en) | 2024-09-05 |
| JP7657855B2 (ja) | 2025-04-07 |
| EA201992612A1 (ru) | 2020-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024201701B2 (en) | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis | |
| JP7485815B2 (ja) | 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 | |
| EP3876943A2 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| AU2020325721A1 (en) | GnRH antagonists for the treatment of estrogen-dependent disorders | |
| AU2020325655A1 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| AU2019373349B2 (en) | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis | |
| EA044130B1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза | |
| HK40116843A (en) | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss | |
| EA049129B1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери | |
| HK40027583A (en) | Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss | |
| HK40027583B (en) | Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230602 |
|
| EEER | Examination request |
Effective date: 20230602 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240729 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241128 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250203 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250530 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250530 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250602 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250602 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250725 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250806 |